Picture Kentro Design Corporate and Web Design Berlin 650x65px
Organisation › Details

SynOx Therapeutics Ltd.

SynOx is a clinical stage biopharmaceutical company. It is a spin out from Celleron Therapeutics Ltd, an oncology company focused on the clinical development of new and innovative therapies to treat cancer. SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue. SynOx is led by a team of experts that combines biotech and pharma experience with a successful track record of developing and bringing products to market. It is backed by a strong investor syndicate – HealthCap, Medicxi, Forbion and Gimv. *


Period Start 2020-11-19 existent (s-off)
  Today Celleron Therapeutics Ltd.
  Predecessor Celleron Therapeutics Ltd.
Products Industry emactuzumab
  Industry 2 drug development
Person Person La Thangue, Nick (SynOx Therapeutics 202011 CEO)
Region Region Dublin
  Country Ireland, Republic of
  City n. a. Dublin
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for �About Section�: SynOx Therapeutics Ltd.. (11/19/20). "Press Release: SynOx Therapeutics Raises €37M in Series A Financing. HealthCap and Medicxi Co-lead, Joined by Forbion and Gimv". Dublin.
Record changed: 2020-11-19


Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for SynOx Therapeutics Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top